Profund Advisors LLC Bristol Myers Squibb CO Transaction History

Profund Advisors LLC

$2.59 Billion
Q3 2024

A detailed history of Profund Advisors LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Profund Advisors LLC holds 42,841 shares of BMY stock, worth $2.49 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

42,841

Previous 41,794 2.51%

Holding current value

$2.49 Million

Previous $1.74 Million 27.78%

% of portfolio

0.09%

Previous 0.07%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$39.66 - $51.75 $41,524 - $54,182	1,047 Added 2.51%	42,841 $2.22 Million
Q2 2024 Aug 13, 2024	SELL	$40.25 - $52.99 $26,082 - $34,337	-648 Reduced 1.53%	41,794 $1.74 Million
Q1 2024 May 08, 2024	SELL	$47.98 - $54.4 $131,992 - $149,654	-2,751 Reduced 6.09%	42,442 $2.3 Million
Q4 2023 Feb 14, 2024	BUY	$48.48 - $57.85 $147,379 - $175,864	3,040 Added 7.21%	45,193 $2.32 Million
Q3 2023 Nov 13, 2023	SELL	$57.89 - $64.73 $37,396 - $41,815	-646 Reduced 1.51%	42,153 $2.45 Million
Q2 2023 Aug 10, 2023	BUY	$63.71 - $70.74 $58,931 - $65,434	925 Added 2.21%	42,799 $2.74 Million
Q1 2023 May 11, 2023	SELL	$65.71 - $74.53 $44,157 - $50,084	-672 Reduced 1.58%	41,874 $2.9 Million
Q4 2022 Feb 02, 2023	SELL	$68.48 - $81.09 $45,950 - $54,411	-671 Reduced 1.55%	42,546 $3.06 Million
Q3 2022 Nov 04, 2022	SELL	$0.13 - $76.84 $346 - $205,009	-2,668 Reduced 5.81%	43,217 $3.07 Million
Q2 2022 Aug 01, 2022	SELL	$72.62 - $79.98 $445,160 - $490,277	-6,130 Reduced 11.79%	45,885 $3.53 Million
Q1 2022 May 10, 2022	SELL	$61.48 - $73.72 $482,495 - $578,554	-7,848 Reduced 13.11%	52,015 $3.8 Million
Q4 2021 Feb 08, 2022	BUY	$53.63 - $62.52 $83,555 - $97,406	1,558 Added 2.67%	59,863 $3.73 Million
Q3 2021 Nov 12, 2021	BUY	$59.17 - $69.31 $24,259 - $28,417	410 Added 0.71%	58,305 $3.45 Million
Q2 2021 Aug 12, 2021	BUY	$61.91 - $67.42 $23,649 - $25,754	382 Added 0.66%	57,895 $3.87 Million
Q1 2021 May 14, 2021	SELL	$59.34 - $66.74 $359,244 - $404,043	-6,054 Reduced 9.52%	57,513 $3.63 Million
Q4 2020 Feb 09, 2021	BUY	$57.74 - $65.43 $6,466 - $7,328	112 Added 0.18%	63,567 $3.94 Million
Q3 2020 Nov 13, 2020	SELL	$57.43 - $63.64 $716,439 - $793,909	-12,475 Reduced 16.43%	63,455 $3.83 Million
Q2 2020 Aug 03, 2020	BUY	$54.82 - $64.09 $818,462 - $956,863	14,930 Added 24.48%	75,930 $4.47 Million
Q1 2020 May 15, 2020	SELL	$46.4 - $67.43 $789,913 - $1.15 Million	-17,024 Reduced 21.82%	61,000 $3.4 Million
Q4 2019 Feb 18, 2020	BUY	$49.21 - $64.19 $1.16 Million - $1.51 Million	23,476 Added 43.04%	78,024 $5.01 Million
Q3 2019 Nov 12, 2019	SELL	$42.77 - $50.71 $368,762 - $437,221	-8,622 Reduced 13.65%	54,548 $2.77 Million
Q2 2019 Aug 13, 2019	SELL	$44.62 - $49.34 $448,252 - $495,669	-10,046 Reduced 13.72%	63,170 $2.87 Million
Q1 2019 May 15, 2019	SELL	$45.12 - $53.8 $174,794 - $208,421	-3,874 Reduced 5.03%	73,216 $3.49 Million
Q4 2018 Feb 14, 2019	SELL	$48.76 - $63.23 $882,263 - $1.14 Million	-18,094 Reduced 19.01%	77,090 $4.01 Million
Q3 2018 Nov 13, 2018	BUY	$55.19 - $62.25 $1.24 Million - $1.4 Million	22,431 Added 30.83%	95,184 $5.91 Million
Q2 2018 Aug 13, 2018	SELL	$50.53 - $62.98 $308,536 - $384,555	-6,106 Reduced 7.74%	72,753 $4.03 Million
Q1 2018 May 14, 2018	SELL	$59.92 - $68.98 $256,397 - $295,165	-4,279 Reduced 5.15%	78,859 $4.99 Million
Q4 2017 Feb 14, 2018	SELL	$59.94 - $65.35 $1.33 Million - $1.45 Million	-22,232 Reduced 21.1%	83,138 $5.1 Million
Q3 2017 Nov 13, 2017	BUY	$55.23 - $63.74 $166,684 - $192,367	3,018 Added 2.95%	105,370 $6.72 Million
Q2 2017 Aug 11, 2017	BUY	N/A	102,352	102,352 $5.7 Million

Others Institutions Holding BMY

# of Institutions

2,533

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $124B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.

Account

Profund Advisors LLC Bristol Myers Squibb CO Transaction History